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Objective: To compare the clinical characteristics and outcomes in patients with
stable angina who have undergone chronic total occlusion (CTO) percutaneous coro-
nary intervention (PCI) in native arteries with or without prior coronary artery bypass
grafting (CABG) surgery in a national cohort.
Background: There are limited data on outcomes of patients presenting with stable
angina undergoing CTO PCI with previous CABG.
Methods: We identified 20,081 patients with stable angina who underwent CTO PCI
between 2007–2014 in the British Cardiovascular Intervention Society database.
Clinical, demographical, procedural and outcome data were analyzed in two groups;
group 1-CTO PCI in native arteries without prior CABG (n = 16,848), group 2-CTO
PCI in native arteries with prior CABG (n = 3,233).
Results: Patients in group 2 were older, had more comorbidities and higher preva-
lence of severe left ventricular systolic dysfunction. Following multivariable analysis,
no significant difference in mortality was observed during index hospital admission
(OR:1.33, CI 0.64–2.78, p = .44), at 30-days (OR: 1.28, CI 0.79–2.06, p = .31) and
1 year (OR:1.02, CI 0.87–1.29, p = .87). Odds of in-hospital major adverse cardiovas-
cular events (MACE) (OR:1.01, CI 0.69–1.49, p = .95) and procedural complications
(OR:1.02, CI 0.88–1.18, p = .81) were similar between two groups but procedural
success rate was lower in group 2 (OR: 0.34, CI 0.31–0.39, p < .001). The adjusted
risk of target vessel revascularization (TVR) remained similar between the two groups
at 30-days (OR:0.68, CI 0.40–1.16, P-0.16) and at 1 year (OR:1.01, CI 0.83–1.22,
P-0.95).
Conclusion: Patients with prior CABG presenting with stable angina and treated with
CTO PCI in native arteries had more co-morbid illnesses but once these differences
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were adjusted for, prior CABG did not independently confer additional risk of mortality,
MACE or TVR.
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1 | INTRODUCTION
Chronically occluded coronary arteries (CTO) are present in up to 20%
of diagnostic angiograms and percutaneous coronary intervention
(PCI) for chronic totally occluded (CTO) coronary arteries is rapidly evolv-
ing.1 A significant proportion of these patients are managed with optimal
medical therapy (OMT), and only a minority of these individuals receive
percutaneous (10–22%) or surgical (22–26%) revascularisation.2,3 Clinical
data has indicated the association between successful CTO revasculari-
zation and better clinical outcomes compared to unsuccessful CTO PCI
procedures.4,5 These studies demonstrated significant symptom relief,
and improved quality of life and exercise tolerance but did not show sig-
nificant differences in mortality.
Patients with prior CABG surgery often have complex coronary
anatomy due to more advanced atherosclerosis and calcification.6
These patients have very high prevalence of CTO lesions and approxi-
mately half of post CABG patients undergoing coronary angiography
have a native CTO coronary artery.2 In the Prague 4 trial, only one in
four SVGs to CTOs remained patent 1 year after CABG surgery.7 Due
to increased age, frailty and multiple comorbid illnesses, further
bypass surgery is rarely performed, leaving PCI as the treatment of
choice. Consequently, there is an increasing interest in treating such
CTOs with PCI, even though CTO PCI in prior CABG patients is more
challenging, associated with more procedural complexity and lower
success rates than CTO PCI in patients without a prior history of
CABG.8 This lesion subset remains the most technically challenging.
The long-term clinical outcomes of CTO PCI in patients with prior
CABG have only received limited evaluation in large clinical studies,
and it remains unclear whether higher procedural complexity encoun-
tered during CTO PCI in prior CABG patients is also translated into
adverse outcomes on follow up.8,9 We therefore sought to describe
the early and late clinical outcomes of CTO PCI in patients presenting
with stable angina and had prior history of CABG in a large, unse-
lected national cohort from the database of the British Cardiovascular
Intervention Society (BCIS).
2 | MATERIALS AND METHODS
This study consists of national data for all patients who have under-
gone CTO PCI in native coronary arteries in England and Wales from
January 2007 to December 2014. The British Cardiovascular Inter-
vention Society (BCIS) maintains data prospectively on PCI proce-
dures throughout United Kingdom, and whole process is monitored
by the National Institute of Cardiovascular Outcomes Research
(NICOR). The data that supports findings of this study are available
from NICOR. Restrictions apply to the availability of these data, which
were used under license for this study. Data are available from the
authors with the permission of NICOR. The protocol, governance and
quality of these data have previously been validated and publi-
shed.10,11 In 2014, approximately 98% of all PCI procedures per-
formed in the National Health Service (NHS) hospital in England &
Wales were recorded on this National database (www.bcis.org.uk/).
The BCIS database consists of 113 clinical, demographical, procedural
and outcomes variables with approximately 80,000 new entries sup-
plemented each year.10,11 BCIS records are linked with Office of
National Statistics (ONS) data for mortality tracking in all patients
from England & Wales by using their unique National Health Service
(NHS) numbers. Patients from Scotland and Northern Ireland were
not included in this study due to the absence of the ONS-linked mor-
tality data. All patients who received CTO PCI in the setting of an
acute coronary syndrome (ACS), or if the data were missing for age,
sex and mortality after discharge, were not included in this analysis
(Figure 1). Data were collected around patients' clinical & demographi-
cal features, risk profile and comorbid conditions as well as aspects of
interventional practice and adjunctive pharmacotherapy. All-cause
mortality data were captured during index hospital admission, at
30-days and 1-year following the PCI procedure. We also analyzed in-
hospital major adverse cardiovascular events (MACE; defined as a
composite of in-hospital mortality, in-hospital myocardial infarction,
and target vessel revascularization), procedural complications including
coronary perforation, major in-hospital bleeding and in-hospital stroke.
We defined in-hospital major bleeding as a composite of clinical tamp-
onade after coronary perforation, intracerebral bleed, gastrointestinal
bleed, blood or platelet transfusion, retroperitoneal hematoma, or an
arterial access site hemorrhage. We also examined a composite end-
point of “any procedural complication” defined as including aortic dis-
section, coronary perforation, DC cardioversion, heart block requiring
pacing, no flow/slow flow phenomenon, need ventilation or cardiogenic
shock-following the procedure. We also assessed frequency of target
vessel revascularization (TVR) at 30 days and 1 year. TVR was defined
if patient underwent a second PCI procedure in same coronary artery.
Furthermore, we analyzed temporal changes in interventional practice
for these patients from 2007–2014.
A CTO lesion was defined as complete occlusion with Thromboly-
sis in Myocardial Infarction (TIMI) flow grade 0 antegrade through the
affected segment of >3 months duration as per previous analyses
published from the BCIS dataset.12,13 We analyzed data by the
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number of enabling strategies (ES) used in the index procedure as a
marker of procedural complexity as per our previous analyses.14 ES to
facilitate CTO-PCI were described as one of the following: dual arte-
rial access, rotational or laser atherectomy, intravascular ultrasound
(IVUS), use of penetration catheters (recorded in the BCIS dataset as
Fine cross, corsair, Tornus) or CrossBoss / Stingray balloon.
The PCI cohort was divided into two groups: (group 1) CTO PCI in
patients without a history of CABG and (group 2) CTO PCI in patients
with prior CABG. For descriptive statistical analysis, continuous vari-
ables were presented as median and interquartile ranges, whereas cate-
gorical variables were presented using frequencies and proportions.
Chi-square tests were applied to evaluate group differences for cate-
gorical variables, while rank sum test were used for continuous vari-
ables. We applied multiple imputations with chained equations to
impute data for all variables with missing records. We applied multivari-
able logistic regression analysis to assess the risk of adverse outcomes
between two groups. In multivariable analysis, we adjusted age, gender,
year of procedure, radial access, femoral access, Body Mass Index
(BMI), angina class, New York Heart Association (NYHA) class shortness
of breath, prior history of smoking, previous history of myocardial
infarction, family history of coronary artery disease (CAD), ejection frac-
tion, circulatory support, history of hypercholesterolemia, history of
hypertension, history of peripheral vascular disease, history of cerebro-
vascular accident, history of diabetes mellitus, use of drug-eluting
eluted stents (DES) and use of ES on imputed data.
Furthermore, we applied propensity score matching (PSM) on
imputed data to estimate the average treatment effect, adjusting for
baseline differences between the two groups of interest. One to one
matching with replacements was performed, followed by logistic
regression analysis (the sole predictor being group membership) to
gain the average treatment effect. We also performed Kaplan–Meier
survival estimates for 30-days and 1-year mortality. Log-Rank test
was applied to assess the difference between two groups. Stata 14.2
statistical package was used for all analyses. All statistical analyses
were two-tailed, and an alpha of 5% used throughout.
3 | RESULTS
3.1 | Study cohort
Our study cohort consisted of 20,081 patients who received at least
1 CTO PCI procedure in native coronary arteries in England & Wales
from January 2007 to December 2014. The inclusion and exclusion of
the population for this analysis is presented in Figure 1. Out of 20,081
total patients in this cohort, 16,848 (84%) CTO PCI was performed in
patients who had no prior history of CABG surgery whilst 3,233 (16%)
procedures were performed in patients with prior CABG (Table 1).
The median follow-up of the entire cohort was 3.84 (IQR 2–5.86)
years. Temporal changes in practice from 2007–2014 are illustrated in
Figure 2. The rate of CTO PCI in prior CABG patients of the total
CTO PCI cohort ranged from 15% to 18% during study period.
3.2 | Clinical characteristics
Significant differences were observed in demographics, clinical and
procedural characteristics between the two groups (Table 1). Patients
F IGURE 1 Illustration of study
inclusion & exclusion criteria: Consort
diagram to show to show all participant
inclusion and exclusion. CABG; coronary
artery bypass grafts; CTO, chronic total
occlusion; PCI, percutaneous coronary
intervention [Color figure can be viewed
at wileyonlinelibrary.com]
SHOAIB ET AL. 3
TABLE 1 Clinical Characteristics
Variable Missing data from total CTO PCI in CABG Naïve (16,848) CTO PCI in prior CABG (3,233) p value
Median age (IQR) 0 63 (56–71) 68 (61–74) <.001
Female sex (%) 0 3,393 (24%) 450 (14%) <.001
Body mass index, median (IQR) 6,017 29 (26–32) 29 (29–32) .73
CCS class, mean (SD) 1,211 3.2 (0.85) 3.4 (0.82) <.001
NYHA class, mean (SD) 1,665 1.88 (0.75) 2.01 (0.78) <.001
Smoking history (%) 1,784 9,928 (64%) 1,828/ (63%) .19
Diabetes mellitus (%) 635 3,424/ (21%) 986 (32%) <.001
Hypertension (%) 831 9,826 (61%) 2,122 (69%) <.001
Hypercholesterolaemia (%) 831 10,570 (65%) 2,134 (69%) <.001
Previous PCI (%) 167 5,574 (33%) 1,567 (50%) <.001
Previous MI (%) 1,284 6,164 (39%) 1,755 (59%) <.001
Previous CVA (%) 831 569 (4%) 152 (5%) <.001
Peripheral vascular disease (%) 831 890 (6%) 302 (10%) <.001
Previous renal disease (%) 845 132 (0.81%) 45 (1.49%) <.001
Family history of heart disease 2,137 7,991 (53%) 1,595 (57%) <.001
Left ventricular systolic function
Good (LVEF >50%) 7,557 8,176 (77%) 1,200 (63%) <.001
Moderate (LVEF 30–50%) 19,78 (19%) 555 (29%)
Poor (LVEF <30%) 455 (4%) 142 (8%)
Access site (AS)
Femoral (%) 0 10,324 (61%) 2,383 (74%) <.001
Radial (%) 0 7,590 (45%) 1,031 (32%) <.001
Glycoprotein IIb/IIIa inhibitor 885 1,379 (9%) 224 (7%) .04
Circulatory support 447 62 (0.38%) 15 (0.48%) .38
DES use 543 11,450 (70%) 1,846 (59%) <.001
IVUS use 0 882 (5%) 173 (5%) .79
Number of stent use
0 210 4,226 (25%) 1,117 (35%) <.001
1 4,212 (25%) 697 (22%)
2 3,880 (24%) 585 (18%)
≥3 4,374 (26%) 780 (25%)
Mechanical ventilator support (%) 1,698 44 (0.28%) 20 (0.73%) <.001
Median follow up period in years (IQR) 0 3.86 (2.01–5.9) 3.72 (1.85–5.75) .004
Enabling strategies (ES)
No ES used 487 11,014 (67%) 1,911 (62%) <.001
No of enabling Strategiesa use = 1 4,108 (25%) 766 (25%)
No of enabling Strategiesa use = 2 1,064 (6%) 285 (9%)
No of enabling Strategiesa use = > 3 341/16,527 (2%) 105/3,067 (4%)
RCA as a target artery 170 8,861 (53%) 1,357 (43%) <.001
LCX as a target artery 170 3,842 (23%) 882 (28%) <.001
LAD as a target artery 170 6,754 (40%) 545 (17%) <.001
Multi vessel PCI 170 2,661 (16%) 623 (20%) <.001
Successful PCI 0 12,303 (73%) 1,626 (50%) <.001
Abbreviations: CCS, Canadian Cardiovascular Society; CTO, chronic total occlusion; CVA, cerebrovascular accident; DES, drugs eluted stents; IQR; inter quartile
range; LVEF, left ventricle ejection fraction; MI, myocardial infarction; NYHA, New York heart association; PCI, percutaneous coronary intervention.
aEnabling Strategies to facilitate CTO-PCI were defined as one of the following: dual arterial access, intravascular ultrasound, atherectomy (rotational or
laser), penetration catheters (recorded in the BCIS database as Tornus, Asahi Intecc, Santa Ana, CA or Gopher Gold, Vascular Solutions, Minneapolis, MN),
microcatheters, or CrossBoss/Stingray balloon.
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who received CTO PCI and had prior history of CABG were older,
more likely to be male, had a higher prevalence of DM, hypertension,
hypercholesterolaemia, previous MI or PCI, peripheral vascular dis-
ease, family history of CAD, and worse angina, breathlessness and left
ventricular systolic dysfunction (LVSD) as compared to those without
CABG. Prior history of smoking, use of circulatory support and intra-
vascular ultrasound during PCI were similar between the two groups.
Patients without CABG were more likely to receive drug elut-
ing stents (DES) (70% vs. 59%, p < .001) and utilization of enabling
strategies was higher when CTO PCI was performed in prior
CABG patients (38% vs. 33% p < .001). More patients received
PCI in left circumflex artery (28% vs. 23%, p < .001) & left main
stem artery (13% vs. 1.45%) in prior CABG patients but lesser in
right coronary artery (43% vs. 53, p < .001) and left anterior des-
cending artery (17% vs. 40%, p < .001) compared to CABG naïve
patients. Success of CTO PCI was higher in CABG naïve patients
(73% vs. 50%, p < .001) compared to those who had previous
CABG surgery.
3.3 | Unadjusted clinical outcomes
The unadjusted clinical outcomes are presented in Table 2. Crude mor-
tality in group 2 was similar during index admission (0.34% vs. 0.18%,
p = .05, higher at 30 days (0.80% vs. 0.43%, p = .005) and at 1 year (3%
vs. 2%, p < .001) compared to group 1. In-hospital transfusion of blood
products (group 1 = 0.23%, group 2 = 0.13%, p = .22), stroke (group
1 = 0.04%, group 2 = 0, p = .25) and MACE (group 1 = 0.91%, group
2 = 1.13%, p = .24) were similar between the two groups. Similarly,
rates of procedural complications (8% vs. 9%, P 0.26) and coronary per-
forations (1.42% vs. 1.51%, P 0.61) were similar in both cohorts.
Finally, the crude rate TVR was similar (0.63% vs. 0.70%, p = .68)
at 30 days, higher at 1 year (6% vs. 5%, p = <.004) and at any time
during study follow up period (7% vs. 6%, p = <.001) in prior CABG
CTO PCI patients compared to CABG naïve (Table 2).
Kaplan–Meier survival estimates at 30 days and 1 year are pres-
ented in Figure 3. In a separate subgroup clinical outcome analyses
according to usage of ES are presented in Supplementary Tables 1–4.
3.4 | Adjusted clinical outcomes
The adjusted risk of procedural complications, short- and long-term
mortality, in-hospital MACE and TVR are presented in Table 3. In the
multivariable statistical analysis, the composite risk of any procedural
complication (OR 1.02, CI 0.88–1.18, P 0.81) and coronary artery per-
foration (OR 0.89, CI 0.64–1.23, P 0.48) were similar between two
groups. After adjustment of baseline characteristics, no significant dif-
ferences in mortality were observed between the groups during index
admission (OR 1.33, CI 0.64–2.78, p = .44), at 30 days (OR 1.28, CI
0.79–2.06, p = .31) and at 1 year of follow up (OR 1.02, CI 0.81–1.29,
p = .87). In addition, no significant differences in in-hospital MACE
were observed between the two cohorts (OR 1.01, CI 0.69–1.49,
p = .95) after adjustment of baseline covariates. Finally, the risk of
TVR was also similar between two groups at each study endpoints
(anytime (OR: 1.05 CI 0.87–1.27, P 0.6), 30 days (OR: 0.68, CI 0.4–
1.16, P 0.16) and 1 year (OR: 1.01, CI 0.83–1.22, P 0.95)).
3.5 | Analysis with propensity score-matching
In a propensity score matching analysis the adjusted composite risk of
any procedural complication (OR 1.05, CI 0.83–1.28, P 0.67), coronary
vessel perforation (OR 0.93, CI 0.49–1.38, p = .77) and in-hospital
MACE (OR: 1.03, CI 0.45–1.62, P – 0.91) did not differ significantly
when CTO PCI undertaken in either prior CABG or CABG naïve
patients (Table 4). Similarly, the adjusted risk of mortality during index
admission (OR 1.30, CI 0.31–2.30, P 0.55), at 30 days (OR 1.24, CI
0.63–1.85, P 0.44) and at 1 year of follow up (OR 1.03, CI 0.76–1.31,
p = .84) were similar between the two groups.
F IGURE 2 Yearly comparisons of CTO PCI in
native arteries from 2007–2014 in patients
with & without prior CABG: Temporal trends of
CTO PCI in CABG naïve Patients vs CTO PCI in
prior CABG patients. CABG; coronary artery
bypass grafts; CTO, chronic total occlusion; PCI,
percutaneous coronary intervention [Color figure
can be viewed at wileyonlinelibrary.com]
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We undertook sensitivity analyses to assess adverse clinical out-
comes according to success of CTO PCI and the results are presented
in supplement Tables 5–6. Adjusted risk of short- and long-term mor-
tality & in-patient MACE were similar between the two groups
whether the CTO PCI was successful or not.
We performed sensitivity analysis according to hospital volume
of total CTO PCI procedures during study period by dividing data into
four quartiles (75th percentile - 270 CTO PCI, 50th percentile –
116 CTO PCI, 25th percentile 37 CTO PCI) and results are presented
in Supplement Tables 7–10. We observed no difference in short- or
long-term adverse clinical outcomes in any of these quartiles either
CTO PCI were attempted in prior CABG or CABG naïve patients. The
adjusted risk of mortality during index admission (OR 1.99, CI 0.83–
4.82, P 0.12), at 30 days (OR 1.61, CI 0.91–2.87, P 0.10) and at 1 year
of follow up (OR 0.92, CI 0.655–1.30, p = .64) were similar between
the two groups in most high-volume hospital quartile. Similar results
were obtained when most high-volume quartile used > = 1 ES during
CTO PCI (supplement Table 8).
We undertook another sensitivity analysis by consultant volume
of total CTO procedures by dividing the data into four quartiles (75th
percentile – 58 CTO PCI, 50th percentile 31CTO PCI, 25th percentile
– 19 CTO PCI) and results are presented in supplement Tables 11–14.
Similarly, the adjusted risk of mortality during index admission
(OR 1.91, CI 0.67–5.4, P 0.23), at 30 days (OR 1.43, CI 0.70–2.92, P =
.32) and at 1 year of follow up (OR 0.92, CI 0.655–1.30, p = .64) were
similar between the two groups in the most experienced operators'
quartile. No difference in adverse clinical outcomes were observed
when the most experienced consultant cohort used one or more ES
(supplement Table 12).
Supplement Figure 1 is demonstrating adjusted spline analysis
for ES use by the year of procedure. We observed lower probability
of ES used during early years of study which gradually rise with
time but notice little change during last 2 years of study (2013–14).
We performed two further sensitivity analyses in view of spline
analysis results, first by inclusion of patients who received CTO PCI
in 2013–14 and second who received in 2011–2014. We again
observed similar results and did not observe any difference in
adverse clinical outcomes between two study cohorts (Supplement
Tables 15–16).
In another multivariable sensitivity analysis, we assessed clini-
cal outcomes in successful vs unsuccessful CTO PCI in both study
cohorts separately (Supplement Tables 17–18). In CABG naïve
patients, odds of any procedural complication were lower when
CTO PCI was successful (OR: 0.71, 95% CI 0.61–0.83, p < .001)
compared to unsuccessful procedures, while all other clinical out-
comes were independent from procedure success (Supplement
Table 17). In prior CABG patients, odds of 30-days mortality were
lower when CTO PCI was successful (OR: 0.33, 95% CI 0.13–
0.86, p = .02) compared to unsuccessful procedures, while all
other clinical outcomes remain similar in both cohorts
(Supplement Table 18).
Figure 4 provides a graphical overview of the main study findings.
TABLE 2 Unadjusted clinical outcomes
Outcome Missing data from total CTO PCI in CABG Naïve (16,848) CTO PCI in prior CABG (3,233) p value
Transfusions (%), n (%) 293 39 (0.23%) 4 (0.13%) .22
In hospital major bleedinga, n (%) 292 189 (1.14%) 38 (1.19%) .8
In-hospital mortality, n (%) 348 29 (0.18%) 11 (0.34%) .05
30-day mortality, n (%) 0 72 (0.43%) 26 (0.80%) .005
1-year mortality, n (%) 0 357 (2%) 105 (3%) <.001
In-hospital MACEb 293 151 (0.91%) 36 (1.1%) .24
In-hospital stroke 293 7 (0.04%) 0 .25
Procedural complications (%)
Any procedural complicationsc 988 1,363 (8%) 278 (9%) .26
Coronary perforation 988 228 (1.42%) 47 (1.54%) .61
Retroperitoneal hemorrhage 551 20 (0.12%) 5 (0.16%) .57
Renal failure/dialysis 293 7 (0.04%) 0 .25
TVR anytime 2,295 841 (6%) 198 (7%) <.001
TVR during 30 days 2,295 105 (0.70%) 17 (0.63%) .68
TVR during 365 days 2,295 740 (5%) 169 (6%) .004
Note: +Emergency CABG or PCI.
Abbreviations: CTO, chronic total occlusion; MACE, major adverse cardiovascular events; PCI, percutaneous coronary intervention; TVR, target vessel
revascularization.
aMajor bleeding: Need blood or platelets transfusions, haemorrhagic stroke, tamponade, retroperitoneal hemorrhage.
bMACE; Major adverse cardiovascular events (defined as a composite of in-hospital mortality, in-hospital myocardial reinfarction, and emergency target
vessel revascularization).
cAny procedural complication includes Aortic dissection, Coronary perforation, Heart block requiring pacing, DC cardioversion, no flow/slow flow
phenomenon, need ventilation, Shock induced by procedure.
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4 | DISCUSSION
Our national real-world analysis suggests that patients with a prior
history of CABG surgery who undergo CTO PCI are older, have more
complex disease necessitating greater use of enabling strategies and
have a greater burden of co-morbid illnesses compared to those who
have never had CABG surgery. Following adjustment for these differ-
ences in baseline characteristics, there was similar adjusted risk of any
procedural complications; vessel perforation, short- and long-term
mortality, TVR and in-hospital MACE between the two groups and
these results were independent of procedure success. To our knowl-
edge, this is the first national analysis that compares and contrasts
clinical outcomes in prior CABG versus CABG naïve patients undergo-
ing CTO PCI in native coronary arteries.
The relationship between CABG surgery and more aggressive
progression of atherosclerosis in native coronary arteries is well
reported in literature.15,16 Sakakura et al. demonstrated that CTO
lesions in prior CABG patients had higher degree of calcification,
moderate negative remodeling and higher prevalence of blunt stumps
compared to CABG naïve.17 These angiographic features are also
associated with challenging recanalization process and incorporated in
risk scores to predict technical failure, for instance in the J-CTO and
RECHARGE (REgistry of CrossBoss and Hybrid procedures in FrAnce,
the NetheRlands, BelGium and UnitEd Kingdom) scores.18,19 In many
other studies, prior CABG patients were found to be older, having
more comorbid conditions compared to those without prior CABG, in
line with our findings. Therefore, taking all these factors into account,
it is perhaps not surprising that several studies have demonstrated
that a previous history of CABG is a predictor of procedural failure of
CTO PCI.8,20-22
Nevertheless, clinical outcomes of CTO PCI according to CABG
status have not been extensively studied. In a retrospective analysis
of 470 CTO (Post CABG n = 175, CABG naïve n = 295) cases treated
with PCI, the rate of in-hospital complications (death, type IV MI,
stroke, tamponade, urgent surgery, major bleeding) was similar
between patients with prior CABG and those without.22 However, at
one-year, a prior history of CABG was associated with higher risk of
MACE. Of course, the small sample size and the fact that this was a
single center experience were limitations of this study. In another
study of 2,058 CTO PCI patients (prior CABG n = 401, CABG naïve
n = 1,657) by Azzalini et al., 24-month target vessel failure was higher
in CTO PCI undertaken in CABG patients (16.1% vs. 9%, p < .001).15
This was an observational study conducted in seven specialist centers
and involving highly experienced CTO PCI operators. Once again,
there are important limitations to this work. Specifically, low event
rates of major complications observed during in hospital admission
(in-hospital death (0.34%), procedure related death (0.19%), stroke
(0.39%), peri-procedural MI (0.78%), perforation (1.3%)) meant that
there was insufficient statistical power to perform multivariable ana-
lyses. Secondly, although TVF was assessed in multi-variable analysis,
individual endpoints were not reported probably due to small event
rates at long term follow up (cardiac death (2%), target vessel MI
(0.83%), TVR (6%)). There are a number of possible explanations that
may contribute to the differences between our observations and
these. Firstly, in the Azzalini study, their sample included 11% ACS
patients, whereas our study population were comprised of stable
angina patients only. Secondly, due to small overall numbers in their
study, individual in-hospital clinical outcomes were underpowered
(seven deaths and eight strokes in 2,058 patients) to assess real differ-
ences between the study cohorts. Thirdly, 14% of patients were lost
to follow up in Azzalini study, compared to our study where we have
followed up mortality data of all the participants included. Fourthly,
different endpoints were studied. Azzalini & colleagues assess TVF
(a composite endpoint of cardiac death, target vessel myocardial
infarction, ischemia driven TVR), whereas we analyzed target vessel
revascularization and mortality as individual endpoints. Finally, the
centers included in the analysis of Azzalini et al. were expert CTO cen-
ters and the complexity of CTO procedures may have been greater
than the CTO procedures undertaken in a national analysis, a factor
that may magnify any differences in outcomes between the two
cohorts studied, particularly for more complex CTO cases.
F IGURE 3 Comparison of Kaplan-Mier survival estimates of CTO
PCI between study groups: KM survival estimates at 30 days and
1 year between two groups. CABG; coronary artery bypass grafts;
CTO, chronic total occlusion; PCI, percutaneous coronary intervention
[Color figure can be viewed at wileyonlinelibrary.com]
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Several observational studies have reported the association of
successful CTO PCI with better clinical outcomes compared to non-
successful CTO PCI. These studies demonstrated better symptoms
control, improved self-reported quality of life, exercise tolerance and
significant reduction in myocardial ischemia and modest positive
effect on left ventricular function.4,5,23-25 Randomized control clinical
trials like DECISION-CTO and EUROCTO tried to explore survival
benefit of CTO PCI over optimum medical therapy (OMT). In the
DECISION-CTO trial, the 3 years rate of composite endpoint of all
cause death, stroke, MI and revascularization was similar between the
PCI and OMT cohorts (20.6% vs. 19.6%).26 In the EUROCTO trial,
CTO PCI was associated with better symptoms control and improved
quality of life but hard endpoints like cardiovascular death or MI were
similar (5% in PCI arm, 2.9 in OMT, p = .32) between the two groups
TABLE 3 Risk of Adverse Outcomes following multivariate adjustments
Outcome
Adjusted ORa as compare to reference (CTO PCI in
CABG naive) p value 95% CI
Any procedural complications, n of
observations = 19,914
OR 1.02 .81 0.88–1.18
Coronary artery perforation as procedural
complication, n = 20,079
OR 0.89 .48 0.64–1.23
In-hospital mortality n of observations = 20,081 OR 1.33 .44 0.64–2.78
Procedural success, n = 20,077 OR: 0.34 <.001 0.31–0.38
30-day mortality n of observations = 20,079 OR 1.28 .31 0.79–2.06
1-year mortality, n of observations = 20,079 OR 1.02 .87 0.81–1.29
In-hospital MACE, n = 20,081 OR 1.01 .95 0.69–1.49
TVR anytime (n = 18,134) OR 1.05 .6 0.87–1.27
TVR 30 days (n = 18,134) OR 0.68 .16 CI 0.40–1.16
TVR 365 days (n = 18,134) OR 1.01 .95 0.83–1.22
Note: OR, odds ratio and MACE, Major adverse cardiovascular events (defined as a composite of in-hospital mortality, in-hospital myocardial reinfarction,
and emergency target vessel revascularization).
Abbreviations: CI, confidence interval; CTO, chronic total occlusion; MACE, major adverse cardiovascular events; n, number for analysis; OR, odds ratio;
PCI, percutaneous coronary intervention; TVR, target vessel revascularization.
aAdjusted for Age, gender, year of procedure, radial access, femoral access Body Mass Index, Angina class, NYHA class, prior history of (H/O) smoking,
prior H/O Myocardial infarction, ejection fraction, family H/O coronary artery disease, circulatory support, prior H/O hypercholesterolemia, prior H/O
hypertension, prior H/O peripheral vascular disease, prior H/O Cerebrovascular accident, prior H/O Diabetes Mellitus, year of procedure, use of Drug
eluted stents & use of enabling strategies on imputed data.
TABLE 4 Propensity Score-Matched Analysis with Average Treatment Effects on imputed data
Outcome Group Coefficienta (95% CI)
Odds Ratioa
(95% CI) p value
Any procedural complications (n = 19,706) group 1: CTO PCI in CABG naive Reference
group 2: CTO PCI in prior CABG 0.0040216 (−0.0144907 to 0.022534) 1.05 (0.83–1.28) .67
Perforation- complications (n = 19,704) group 1: CTO PCI in CABG naive Reference
group 2: CTO PCI in prior CABG −0.0010099 (−0.0078223 to 0.0058024) 0.93 (0.49–1.38) .77
In-hospital mortality (n = 19,706) group 1: CTO PCI in CABG naive Reference
group 2: CTO PCI in prior CABG 0.00102 (−0.0023474 to 0.0043874) 1.30 (0.31–2.30) .55
30-day mortality (n = 19,704) group 1: CTO PCI in CABG naive Reference
group 2: CTO PCI in prior CABG 0.0018778 (−0.0029137 to 0.0066693) 1.24 (0.63–1.85) .44
1-y mortality (n = 19,704) group 1: CTO PCI in CABG naive Reference
group 2: CTO PCI in prior CABG 0.0008425 (−0.0071284 to 0.0088133) 1.03 (0.76–1.31) .84
In-hospital MACE (n = 19,706) group 1: CTO PCI in CABG naive Reference
group 2: CTO PCI in prior CABG 0.0003704 (−0.0061776 to 0.0069185) 1.03 (0.45–1.62) .91
aAdjusted for Age, gender, year of procedure, radial access, femoral access Body Mass Index, Angina class, NYHA class, prior history of (H/O) smoking,
prior H/O Myocardial infarction, ejection fraction, family H/O coronary artery disease, circulatory support, prior H/O hypercholesterolemia, prior H/O
hypertension, prior H/O peripheral vascular disease, year of procedure, prior H/O Cerebrovascular accident, prior H/O Diabetes Mellitus, use of Drug
eluted stent & use of enabling strategies on imputed data.
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at 3 years of follow up.27 In a recently published systematic review
and meta-analysis of 17 studies and a total of 11,493 patients, a sta-
tistically significant association between CTO PCI and lower risk of
all-cause mortality, cardiac death, MI, MACE was reported when com-
pared to medical therapy.28 However, this was predominantly driven
by observation cohorts which would be limited by unmeasured con-
founders. The randomized trials considered in this meta-analysis
showed no significant associations between CTO PCI and overall mor-
tality, cardiac death, repeat revascularization and MACE.
One of the dominant drivers for increased CTO PCI in CABG
patients is the perception that the outcome from SVG PCI is unsat-
isfactory as a medium- and long-term solution. Thus, many observa-
tional studies indicate that PCI to SVG is less efficacious than to
native coronary arteries in CABG patients,29,30 being associated
with lower success, higher complication rates and adverse long-term
outcomes (mortality, myocardial infarction, and target vessel revas-
cularization) as compared to PCI undertaken in native coronary
arteries. Therefore, in contemporary interventional practice, it is
increasingly believed that lesions in native coronary arteries should
be preferred target for PCI in the prior CABG patients, even if these
are CTOs.29
The current analysis adds to our current knowledge base about
CTO PCI. Our analysis shows that after adjustment of baseline clin-
ical differences, the risk of CTO PCI procedure-related complica-
tions, in-hospital MACE, stroke, short- and long-term morality are
not increased in those with a history of prior CABG presenting with
stable angina. Based upon these findings, in present era of high suc-
cess and acceptable complication rates, patient selection for CTO
PCI should be focused on anticipated patient benefits instead of
concern about perceived increased procedural complexity and pro-
cedural failure by virtue of prior CABG surgery. Our study confirms
that prior CABG status does not affect complication rates in
patients undergoing CTO PCI.
5 | LIMITATIONS
BCIS endeavors to record data about every PCI procedure undertaken
in the UK and the nationwide participation from all NHS hospitals in
the UK make it a national representation. This dataset also captures
information from almost all patients received PCI in UK from a wide
range of spectrum. Our large sample size gives us sufficient statistical
power to capture differences in clinical outcomes between the patient
groups studied. Moreover, majority of these patients are often
excluded or under-represented in clinical trials, and so our data repre-
sents important evidence in this context. However, due to inclusion
of all the CTO procedures in this study, the overall cohort might be
heterogenous where some CTO lesions are relatively low risk, or per-
formed by non-CTO or less experienced operators, or in low volume
hospitals. We tried to assess these potential limitations in our series
of adjusted sensitivity analyses (Supplementary Tables 7–16) but did
not find any significant difference in terms of adverse clinical
F IGURE 4 Central illustration Figure. Summary figure: CABG, coronary artery bypass grafts; CTO, chronic total occlusion; CVA,
cerebrovascular accident; CVA, cerebrovascular accident; DM, diabetes mellitus; MI, myocardial infarction; PCI, percutaneous coronary
intervention; PVD, peripheral vascular disease; LVSD, left ventricular systolic dysfunction [Color figure can be viewed at wileyonlinelibrary.com]
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outcomes between the two cohorts, neither in the high-volume cen-
ters nor by experience of CTO PCI operators.
However, our study has several other limitations. First, it is a retro-
spective analysis of prospectively collected national data and has all the
inherent bias ascribed to this kind of study design. Secondly, though
mortality tracking within England and Wales is well structured through
ONS linkage, the cause of death is not available. Thirdly, all other clini-
cal outcomes and post procedural complications are self-reported, with-
out formal adjudication, and thus susceptible to reporting bias.
Fourthly, apart from mortality and TVR, BCIS dataset does not record
other post discharge clinical outcomes like readmission due to ACS or
stroke. Fifth the BCIS dataset does not record the complexity of CTO
lesions according to modern scoring systems (J-CTO or RECHARGE).
Sixth, in pre-CABG cohort, the BCIS dataset does not capture informa-
tion whether CTO PCI is attempted in a grafted or un-grafted vessel
which may affect the overall complexity of procedure. Finally, the data-
base dose not collect data regarding procedural time, radiation dose
and contrast volume during the CTO PCI procedures.
6 | CONCLUSION
Our study demonstrates that approximately one in six CTO PCI proce-
dures were undertaken in patients with a prior history of CABG in
England & Wales. These patients are a higher risk group that are older,
have more comorbid conditions and have more complex disease. After
adjustment of differences in baseline clinical and procedural charac-
teristics, we report that clinical outcomes are not significantly differ-
ent between patients who undergo CTO PCI with or without a prior
history of CABG. These data indicate that history of CABG is not a




The data that supports findings of this study are available from
NICOR. Restrictions apply to the availability of these data, which were
used under license for this study. Data are available from the authors
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